Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Implementing HIV screening.

Robert S Janssen1

  • 1Division of HIV/AIDS and Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. rxj1@cdc.gov

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|February 8, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A narrative review of immune-mediated adverse events in clinical trials of CpG oligonucleotide toll-like receptor 9 agonists.

Vaccine·2026
Same author

Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Hepatitis B vaccination with HepB-CpG in people living with HIV: a narrative review.

Expert review of vaccines·2025
Same author

Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant compared with Boostrix in healthy adults and adolescents.

Vaccine·2024
Same author

Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.

Vaccine·2023
Same author

Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study.

Human vaccines & immunotherapeutics·2022
Same journal

Antibiotic Treatment Duration for Uncomplicated Monomicrobial Enterococcal Bloodstream Infection: A Multicenter Target Trial Emulation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Larger Blood Volume Increases Detection of Fastidious Mycobacteria and Fungi in Blood Culture.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Anticalcitonin: Limited utility of a context-dependent biomarker demonstrated in another real-world data set.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Procalcitonin Testing in Community-Acquired Pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Wanted: A Relevant Correlate of Protection for Dengue Vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
See all related articles

Updated US guidelines recommend human immunodeficiency virus (HIV) testing for all adults aged 13-64. This aims to increase early detection and improve treatment and prevention strategies for undiagnosed HIV infections.

Area of Science:

  • Public Health
  • Infectious Disease Epidemiology
  • Clinical Medicine

Background:

  • Recent revisions to US human immunodeficiency virus (HIV) testing recommendations have been issued.
  • A key objective is to decrease the number of individuals unaware of their HIV infection status.

Purpose of the Study:

  • To outline the updated guidelines for HIV screening in the United States.
  • To emphasize the importance of early HIV detection for improved patient outcomes and public health strategies.

Main Methods:

  • The revised guidelines recommend universal HIV screening for individuals aged 13-64 years in all healthcare settings.
  • Informed consent is required, with patients notified of the test and given the option to decline.
  • Annual screening is advised for individuals identified as high-risk for HIV infection.

Related Experiment Videos

Main Results:

  • Wider HIV screening is anticipated to increase the identification of individuals with unrecognized infections.
  • Early identification facilitates timely initiation of treatment and management of HIV.
  • Enhanced screening allows for more precise targeting of HIV prevention efforts.

Conclusions:

  • The updated recommendations promote broader HIV testing to reduce undiagnosed infections.
  • Increased screening is expected to improve individual health outcomes and contribute to effective HIV control strategies.
  • Universal screening and targeted annual testing are crucial components of modern HIV management and prevention.